MCRB - Seres Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
MCRB price evolution
MCRB
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $136.15 | $178.1 | $237.71 | $103.03 |
| Short term investments | $11.7 | |||
| Net receivables | $8.67 | $16.86 | $7.56 | |
| Inventory | $29.65 | $18.52 | $5.34 | |
| Total current assets | $175.41 | $214.39 | $251.24 | $116.08 |
| Long term investments | $1.4 | $1.4 | $1.4 | $1.4 |
| Property, plant & equipment | $132.25 | $131.67 | $134.31 | $133.22 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $183.19 | $153.31 | $155.15 | $154.11 |
| Total investments | $1.4 | $1.4 | $1.4 | $13.1 |
| Total assets | $358.6 | $367.7 | $406.39 | $270.19 |
| Current liabilities | ||||
| Accounts payable | $3.64 | $8.96 | $12.92 | $12.3 |
| Deferred revenue | $103.09 | $104.89 | $98.56 | $97.21 |
| Short long term debt | $6.68 | $6.28 | $5.47 | $4.78 |
| Total current liabilities | $98.66 | $79.22 | $77.9 | $63.82 |
| Long term debt | $207.26 | $206 | $207.45 | $157.93 |
| Total noncurrent liabilities | $304.8 | $303.6 | $305.88 | $254.25 |
| Total debt | $213.94 | $212.28 | $212.92 | $162.71 |
| Total liabilities | $403.46 | $382.82 | $383.77 | $318.06 |
| Shareholders' equity | ||||
| Retained earnings | -$978.24 | -$936.99 | -$889.13 | -$935.68 |
| Other shareholder equity | -$0 | $0 | ||
| Total shareholder equity | -$44.86 | -$15.12 | $22.61 | -$47.87 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $136.15 | $171.22 | $188 | $116.05 |
| Short term investments | $18.31 | $110.7 | $137.57 | |
| Net receivables | $8.67 | $9.39 | ||
| Inventory | $29.65 | |||
| Total current assets | $175.41 | $194.76 | $303.63 | $268.78 |
| Long term investments | $1.4 | $1.4 | $1.9 | $51.23 |
| Property, plant & equipment | $132.25 | $133.97 | $36.15 | $22.94 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $183.19 | $154.02 | $51.23 | $74.16 |
| Total investments | $1.4 | $19.71 | $112.6 | $188.79 |
| Total assets | $358.6 | $348.78 | $354.86 | $342.94 |
| Current liabilities | ||||
| Accounts payable | $3.64 | $17.44 | $13.73 | $4.02 |
| Deferred revenue | $103.09 | $96.69 | $103.82 | $108.17 |
| Short long term debt | $6.68 | $4.06 | $6.61 | $5.57 |
| Total current liabilities | $98.66 | $85.6 | $82.26 | $46.41 |
| Long term debt | $207.26 | $50.59 | $42.6 | $35.2 |
| Total noncurrent liabilities | $304.8 | $252.41 | $141.09 | $121.78 |
| Total debt | $213.94 | $162.59 | $49.21 | $40.77 |
| Total liabilities | $403.46 | $338 | $223.35 | $168.19 |
| Shareholders' equity | ||||
| Retained earnings | -$978.24 | -$864.51 | -$614.35 | -$548.78 |
| Other shareholder equity | -$0.01 | -$0.06 | -$0.05 | |
| Total shareholder equity | -$44.86 | $10.78 | $131.51 | $174.75 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.06 | $0.31 | $126.47 | -$0.52 |
| Cost of revenue | ||||
| Gross Profit | $0.06 | $0.31 | $126.47 | -$0.52 |
| Operating activities | ||||
| Research & development | $26.85 | $28.25 | $46.79 | $43.97 |
| Selling, general & administrative | $17.23 | $19.99 | $28.05 | $22.47 |
| Total operating expenses | $39.59 | $47.72 | $76.95 | $70.05 |
| Operating income | -$39.53 | -$47.41 | $49.52 | -$70.57 |
| Income from continuing operations | ||||
| EBIT | -$37.22 | -$43.84 | $49.74 | -$69.23 |
| Income tax expense | ||||
| Interest expense | $4.03 | $4.01 | $3.19 | $1.95 |
| Net income | ||||
| Net income | -$41.25 | -$47.85 | $46.55 | -$71.17 |
| Income (for common shares) | -$41.25 | -$47.85 | $46.55 | -$71.17 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $126.33 | $7.13 | $144.93 | $33.22 |
| Cost of revenue | ||||
| Gross Profit | $126.33 | $7.13 | $144.93 | $33.22 |
| Operating activities | ||||
| Research & development | $145.86 | $172.92 | $141.89 | $90.57 |
| Selling, general & administrative | $87.74 | $79.69 | $69.26 | $30.77 |
| Total operating expenses | $234.31 | $253.62 | $209.42 | $121.34 |
| Operating income | -$107.98 | -$246.49 | -$64.49 | -$88.13 |
| Income from continuing operations | ||||
| EBIT | -$100.55 | -$244.14 | -$62.67 | -$86.2 |
| Income tax expense | ||||
| Interest expense | $13.18 | $6.02 | $2.91 | $2.92 |
| Net income | ||||
| Net income | -$113.72 | -$250.16 | -$65.58 | -$89.13 |
| Income (for common shares) | -$113.72 | -$250.16 | -$65.58 | -$89.13 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$41.25 | -$47.85 | $46.55 | -$71.17 |
| Operating activities | ||||
| Depreciation | $4.05 | $3.89 | $3.7 | $3.47 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $5.09 | $8.67 | $13.49 | $6.85 |
| Total cash flows from operations | -$47.5 | -$59.26 | $65.98 | -$76.58 |
| Investing activities | ||||
| Capital expenditures | -$0.88 | -$1.8 | -$1.23 | -$4.07 |
| Investments | $11.75 | $6.81 | ||
| Total cash flows from investing | -$0.88 | -$1.8 | $10.52 | $2.74 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $6.43 | $1.44 | $7.66 | $5.66 |
| Net borrowings | $50.52 | |||
| Total cash flows from financing | $6.43 | $1.44 | $58.18 | $5.66 |
| Effect of exchange rate | $0 | $0 | ||
| Change in cash and equivalents | -$41.95 | -$59.61 | $134.68 | -$68.19 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$113.72 | -$250.16 | -$65.58 | -$89.13 |
| Operating activities | ||||
| Depreciation | $15.11 | $11.85 | $9.22 | $8.89 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $34.1 | $25.48 | $20.22 | $8.82 |
| Total cash flows from operations | -$117.35 | -$228.82 | $6.69 | -$93.61 |
| Investing activities | ||||
| Capital expenditures | -$7.97 | -$9.82 | -$9.57 | -$0.59 |
| Investments | $18.56 | $92.25 | $73.65 | -$158.3 |
| Total cash flows from investing | $10.58 | $82.43 | $64.09 | -$158.89 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $21.19 | $103.9 | $2.13 | $303.42 |
| Net borrowings | $50.52 | $25.7 | -$0.95 | |
| Total cash flows from financing | $71.7 | $129.6 | $1.18 | $303.42 |
| Effect of exchange rate | $0 | -$0 | -$0 | |
| Change in cash and equivalents | -$35.07 | -$16.79 | $71.95 | $50.92 |
News
Fundamentals
| Market cap | $78.86M |
|---|---|
| Enterprise value | $156.65M |
| Shares outstanding | 135.04M |
| Revenue | $126.33M |
|---|---|
| EBITDA | -$85.43M |
| EBIT | -$100.55M |
| Net Income | -$113.72M |
| Revenue Q/Q | -93.44% |
| Revenue Y/Y | 1.67K% |
| P/E ratio | -0.69 |
|---|---|
| EV/Sales | 1.24 |
| EV/EBITDA | -1.83 |
| EV/EBIT | -1.56 |
| P/S ratio | 0.62 |
| P/B ratio | -1.76 |
| Book/Share | -0.33 |
| Cash/Share | 1.01 |
| EPS | -$0.84 |
|---|---|
| ROA | -32.43% |
| ROE | 533.69% |
| Debt/Equity | -8.99 |
|---|---|
| Net debt/EBITDA | -3.13 |
| Current ratio | 1.78 |
| Quick ratio | 1.48 |